DLA Piper’s US life sciences group has hired two IP partners from Hogan Lovells in New York and a litigator from Vinson & Elkins in Texas.
DLA announced that it had added Michael Dougherty and Tony Pezzano to its New York IP and technology team on 19 September.
Both lawyers have represented Merck in a number of patent disputes with generic companies, including successful trials and settlement agreements related to its Invanz antibiotic and the antifungal treatment Noxafil. The pair also regularly work on matters arising from section 337 patent infringement investigations by the US International Trade Commission.
“Michael and Tony bring decades of experience in life sciences litigation, particularly in the pharmaceutical and biotechnology arenas,” said Frank Ryan, global co-chair and US co-char of DLA Piper’s Intellectual Property and Technology practice. “They are exceptionally talented lawyers with a proven record of success at trial, and their unique skill set will strengthen our practice significantly.”
Before joining DLA Piper, Dougherty and Pezzano were partners in Hogan Lovells’ intellectual property media and technology practice group for two years, before which they were partners at King & Spalding.
Also arriving on 19 September was former Vinson & Elkins partner Daniel Tobey, who joined DLA’s litigation practice in Dallas.
A qualified physician, Tobey represents technology, healthcare and life sciences companies in patent disputes and tort and contract cases, including before the Fifth Circuit Court of Appeals and the Delaware Supreme Court.
“Danny is a perfect fit for our global platform, which will allow him to take advantage of his unique background in the life sciences and healthcare fields,” said Loren Brown, co-chair of DLA Piper’s global and US Litigation practices. “Our clients will greatly value his counsel as they seek to navigate a litigation and regulatory environment that is complex and changing constantly.”
“Danny was a valued colleague for many years and we wish him well in his new endeavour,” said John Wander, co-chair of Vinson & Elkins’ complex commercial litigation practice.
Hogan Lovells did not respond to PLN’s request for comment.